Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

AX immunotherapy for prostate cancer in its bioreactor manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product during commercialization.

Conference Call and Webcast

Members of the Cell Genesys management team will host a conference call today, Monday, January 14 at 10:00 a.m. ET to discuss today's announcement. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, http://www.cellgenesys.com. Alternatively, investors may listen to a replay of the call by dialing 800-475-6701 from locations in the United States and 320-365-3844 from outside the United States. The call-in replay and webcast will be available for at least 72 hours following the call. Please refer to reservation number 907247.

About Cell Genesys

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results, analysis
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/19/2014)... development with the growth pace keeping at 20%-30% in last ... size of China separating membrane products ... 16.3%. It is projected that China ... 20% in the upcoming years and that the figure by ... integrated membrane industrial system has taken shape in ...
(Date:12/17/2014)... Los beneficios y ganancias están ... de gasto en investigación y desarrollo   ... de septiembre de 2014) ZEISS aumentó sus ingresos en ... (año anterior: 4.190 millones de euros) a pesar de ... crecieron un 14 por ciento, a 360 millones de ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
(Date:12/21/2014)... (PRWEB) December 21, 2014 Hundreds ... product liability claims involving a class of Type ... to move forward in a federal multidistrict litigation ... of California, Bernstein Liebhard LLP reports. According to ... established a data cut-off date of February 27, ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Recently, one ... world, LunaDress Prom Shop has introduced its ... Christmas Sale, offering big discounts on all its prom ... off. , LunaDress insists on providing top quality dress ... and it is considered as one of the best ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas ... time helping people get their health back. Mission for ... serving those persons in Muskegon County who are unable to ... of life. Dr. Michael Rykse wanted to do a Toy ... and he knew he found that when he heard what ...
(Date:12/21/2014)... Phoenix, AZ (PRWEB) December 21, 2014 ... wide range of heating, cooling, plumbing and other similar ... reviews in 2014 with regard to its expert contracting ... an industry leader that has been serving Arizona for ... pride in providing the absolute best in quality customer ...
(Date:12/21/2014)... SCI explores disability in sports ... barriers for disabled athletes with Aaron Scheidies , ... condition called juvenile macular degeneration, where he loses his ... his athletic ambitions to his vision and how he ... pioneer the way for other blind and visually impaired ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... ... found that women taking AdvaCAL® calcium had the highest bone density increase among 32 ... postmenopausal women, 79 skeletal measures and 7 different types of calcium, including dairy calcium. ... (PRWEB) January ...
... , ... Bone marrow is a leading source of adult stem cells, ... cells is an arduous and often painful process. Now, researchers have found ... new source of valuable and easy-to-obtain regenerative cells called hematopoietic stem and ...
... ... connectors, is utilizing their nano-connector Bi-lobes® to help handle difficult signal routing and ... ... the leading manufacturer of miniature high-rel connectors, is utilizing their nano-connector Bi-lobes® to ...
... ... areas shows that current KOL identification methods produce inaccurate results; relationship models are more ... ... white paper challenges the generally-held notion that scientists who are “productive” in terms ...
... Center have performed the first complete genomic sequencing of ... lead to personalized treatments based on the unique biological ... may unveil new molecular targets for which more effective ... study also may lead to new and better ways ...
... ... ... attract high-value patients, get book deals, CNN expert spots, lucrative speaking engagements, and earn ten ... report high-visibility doctors are as adept at publicity and personal branding as any Hollywood film ...
Cached Medicine News:Health News:Report: AdvaCALCalcium Builds Bone Best 2Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 2Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 3Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 4Health News:Omnetics Nano-to-Flex Connectors Solve Big Problems in Small Spaces 2Health News:Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders 2Health News:Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders 3Health News:UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line 2Health News:UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line 3Health News:Doctors: Memorable or Forgettable? 4 Steps to a High Visibility Practice 2Health News:Doctors: Memorable or Forgettable? 4 Steps to a High Visibility Practice 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: